Clinical Trials | May 08, 2026
Moderna’s mRNA flu vaccine outperforms standard shot in Phase 3 trial
NEJM study shows strong protection across strains
NEJM study shows strong protection across strains
The pharmaceutical giant reported $14.5 billion in revenue, up 5% year-over-year, and reaffirmed its full-year outlook
Growth was supported by stronger COVID vaccine sales and expanded government supply agreements in international markets
Reshaped by COVID-19, rising test demand, and a shift toward decentralized diagnostics, qPCR has evolved from niche academic use to a core clinical engine
Profitability came under strain. Gross profit fell to EUR 246m, with margins narrowing to 23.7% as negative product mix—particularly in Asia Pacific—weighed on performance
C. P. Radhakrishnan urged graduates to uphold ethical standards and maintain a commitment to patient care
Marking three years of the National Diagnostics Catapult (NDxC), the conclave launched the Impact Report and unveiled environmental surveillance kits
The ninth edition of the event brought together over 800 delegates, more than 60 national and international speakers, and 20+ partner organisations across 10 sessions
In his new role, Saran will spearhead the end-to-end launch framework for innovation-led portfolio
The new regimen, delivering 50 mg/5 mL and 28 mg/5 mL doses, offers a higher concentration of the drug for both loading and maintenance phases
Subscribe To Our Newsletter & Stay Updated
